HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases.

AuthorsMelanie S Joy, Reginald F Frye, Kristi Stubbert, Kim R Brouwer, Ronald J Falk, Evan D Kharasch
JournalJournal of clinical pharmacology (J Clin Pharmacol) Vol. 50 Issue 6 Pg. 714-20 (Jun 2010) ISSN: 1552-4604 [Electronic] England
PMID20103693 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antidepressive Agents, Second-Generation
  • Bupropion
  • Aryl Hydrocarbon Hydroxylases
  • CYP2B6 protein, human
  • Cytochrome P-450 CYP2B6
  • Oxidoreductases, N-Demethylating
  • radafaxine
Topics
  • Adult
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (metabolism)
  • Antidepressive Agents, Second-Generation (pharmacokinetics)
  • Aryl Hydrocarbon Hydroxylases (metabolism)
  • Bupropion (analogs & derivatives, pharmacokinetics)
  • Chronic Disease
  • Cytochrome P-450 CYP2B6
  • Female
  • Humans
  • Lupus Nephritis (metabolism)
  • Male
  • Middle Aged
  • Oxidoreductases, N-Demethylating (metabolism)
  • Phenotype
  • Stereoisomerism

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: